Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: There are limited data on trastuzumab-pertuzumab (HP)-based treatments beyond the first-line, HER2+ metastatic breast cancer (MBC) setting. We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response.
Methods: After a run-in phase for eribulin dosing, two cohorts were enrolled (Cohort A-no prior pertuzumab; Cohort B-prior pertuzumab). All patients received eribulin 1.4 mg/m on days 1, 8 with standard-dose HP on day 1 (21-day cycles). The primary endpoint was objective response rate (ORR). Genomic characterization via whole exome sequencing (WES) was completed on tumor DNA and matched germline DNA from 19 patients.
Results: The six-patient run-in established a dose of eribulin 1.4 mg/m with HP. Cohorts A and B enrolled 17 and 7 patients, respectively. Accrual stopped early due to an evolving treatment landscape and slow enrollment. The ORR was 26.3% (95% Confidence Interval [CI] 9.2-51.2%) in Cohort A and 0% in Cohort B (95% CI 0-41.0%). WES revealed more frequent alterations in TP53 (p < 0.05, q > 0.05) in patients without clinical benefit (disease control for < 24 weeks) which was not significant after multiple hypothesis correction.
Conclusion: Eribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a preliminary landscape of somatic alterations in this patient cohort. Our data add to the literature on how genomic alterations may predict for therapy response/resistance, as we work to individualize choices in a quickly evolving HER2+ MBC treatment landscape.
Trial Registration: www.clinicaltrials.gov , NCT01912963. Registered 24 July 2013.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10549-021-06329-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Warfarin reduces circulating white blood cell count: Post-hoc analysis of two randomized trials.
Thromb Res
September 2025
Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Electronic address:
Warfarin is a widely used vitamin K antagonist (VKA) with known pleiotropic effects beyond anticoagulation. Preclinical and case-control evidence suggests that warfarin may affect hematopoiesis, but longitudinal human evidence is lacking. To explore this potential effect, we conducted a post-hoc analysis of participants in the Hokusai-VTE and ENGAGE AF-TIMI 48 trials, which randomized patients to warfarin or the direct oral anticoagulant edoxaban with routine laboratory testing at predefined follow-up visits.
View Article and Find Full Text PDFSmall Extracellular Vesicles as Biomarkers in Sarcoma Follow-Up: Protocol for a Prospective, Multicentric Pilot Study.
JMIR Res Protoc
September 2025
Department of Medical Oncology, Early Phase Unit, Georges-François Leclerc Centre, Dijon, France.
Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death.
View Article and Find Full Text PDFExploring Online Health Information-Seeking Behavior Among Young Adults: Scoping Review.
J Med Internet Res
September 2025
Department of Community Medicine, Faculty of Health, UiT The Arctic University of Norway, Tromsø, Norway.
Background: The ability to access and evaluate online health information is essential for young adults to manage their physical and mental well-being. With the growing integration of the internet, mobile technology, and social media, young adults (aged 18-30 years) are increasingly turning to digital platforms for health-related content. Despite this trend, there remains a lack of systematic insights into their specific behaviors, preferences, and needs when seeking health information online.
View Article and Find Full Text PDFUser Engagement With a Mobile Health App for People Living With HIV: Observational Study Based on an Engagement Evaluation Framework.
J Med Internet Res
September 2025
College of Nursing, Yonsei University, Seoul, Republic of Korea.
Background: Mobile health (mHealth) interventions can be effective for people living with HIV, who are sensitive to privacy breach risks. Understanding the perceived experiences of intervention participants can provide comprehensive insights into potential users and predict intervention effectiveness. Thus, it is necessary to plan engagement measurement and consider ways to enhance engagement during the app development phase.
View Article and Find Full Text PDFChemical Composition, Antioxidant, and Antibacterial Activities of Mezilaurus duckei (Lauraceae).
Chem Biodivers
September 2025
Instituto De Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Mezilaurus duckei, a Brazilian endemic tree species found exclusively in the Amazon Rainforest, is primarily exploited for timber in construction. Due to its endangered status, this study aimed to investigate the chemical profile and biological properties of the ethanolic extract and its phases derived from M. duckei leaves.
View Article and Find Full Text PDF